Beamtree Holdings Ltd · ASX:BMT
Beamtree — H1 2025 Earnings Presentation
25 slides from Beamtree's earnings presentation, Feb 19, 2025
Slide 1: 1H FY25 Results
1H FY25 Results 19th February 2025 Authorised for release by the Board of Directors
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 19th February 2025. This presentation may contain statements that are, or may be deemed to be, forward looking
Slide 3: 1H FY25 Highlights
1H FY25 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: 1H FY25 Financial Highlights
1H FY25 Financial Highlights 10% 31% 5% 101% $3.7M PCP* PCP PCP PCP Reported International Operating Operating Cash Revenue Revenue Expenses Profit Operating cashflow $14.2M $6.2M $14.2M Break even in 1H vs break even in 1H vs 44% of revenue -$0.5m in 1H FY24 -$2.3m in 1H FY24 *Prior Corresponding P
Slide 5: 1H FY25 Highlights
1H FY25 Highlights • Appointed new CEO for next phase of growth • Developed significant pipeline for our autonomous coding market offering in Australia, UK and Canada. • Continued to mature the sales pipeline across all segments. Current sales pipeline is now $61m. • Continued to invest in product d
Slide 6: $60m ARR Target – Reaffirm Conviction
$60m ARR Target – Reaffirm Conviction $60M +40% CAGR $25.5M $22.8M $18.2M FY22 FY23 FY24 2026 Copyright © Beamtree Holdings Limited – All Rights Reserved 5
Slide 7: Accelerating Pipeline and Customer Value Expansion
Accelerating Pipeline and Customer Value Expansion $61M $13m pipeline in later stage Customer Value Expansion 01 ICP (ME & AUS) Top 15 customers on average Pipeline has 02 Autonomous procure 2.7 products. increased by Coding (ME, UK 50% in the last AUS, & CAN) 12 months and $47.5M significantly matu
Slide 8: FY25 Outlook and Targets
FY25 Outlook and Targets Management reaffirms outlook Reported revenue growth Ongoing management of opex of delivering annual recurring expected to be ~10% for FY25. and continued reduction in cash revenue of $60m by end of burn in 2H versus 1H 2026. Forecast reported recurring revenue expected to b
Slide 9: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 8
Slide 10: Creating a better future for health
Creating a better future for health We provide AI decision support and data insights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends in better outcomes Copyright © Beamtree Holdings Limited – All Rights Reserved 9
Slide 11: Beamtree is committed to supporting learning health systems
Beamtree is committed to supporting learning health systems Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency.
Slide 12: The Problems We Help Solve
The Problems We Help Solve Tackle unwarranted Offer revenue Promote Drive variation assurance transparency automation Address equity Bridge knowledge gaps Increase efficiency, Improve quality of access and resource reducing errors of data allocation Copyright © Beamtree Holdings Limited – All Rights
Slide 13: Beamtree: Core International Markets
Beamtree: Core International Markets United Kingdom FY24: Continued strengthening Canada • 68m population relationship with Lean including co- investment into Integrated Coding • 39m population • $377b health expenditure Platform. • $331b health expenditure FY25: Expand Coding opportunities (PICQ an
Slide 14: FY25 Financial Results
FY25 Financial Results Copyright © Beamtree Holdings Limited – All Rights Reserved 13
Slide 15: 1H FY25 Summary Profit and Loss
1H FY25 Summary Profit and Loss 1H FY24 1H FY25 Growth % Annual Recurring Revenue 24.2 25.5 5% Diagnostic 3.4 3.7 11% Coding & data quality assurance 3.9 4.6 19% Clinical decision support 0 .2 0 .2 6% Group Revenue +10% Knowledge networks 5.5 5.7 3% Total Revenue 12.9 14.2 10 % Expenses – people (9.
Slide 16: Strong Track Record of Revenue Growth
Strong Track Record of Revenue Growth ($’M) Revenue Growth +47% +23% +10% Recurring Revenue Growth +23% +11% +10% 14.2 12.9 10.5 6.2 44% 4.7 36% 3.2 31% 7.1 2.1 29% 8.3 64% 8.1 56% 7.3 69% 5.1 71% 1H FY22 1H FY23 1H FY24 1H FY25 Australia International Copyright © Beamtree Holdings Limited – All Rig
Slide 17: Controlled Operating Expense Growth
Controlled Operating Expense Growth ($’M) Expense Growth +33% +19% +5% 14.2 13.5 3.6 25% 11.4 4.2 31% -16% YoY 3.4 30% 8.5 2.8 33% 10.7 75% 9.3 69% +15% YoY 8.0 70% 5.7 67% 1H FY22 1H FY23 1H FY24 1H FY25 Staff Non-staff Copyright © Beamtree Holdings Limited – All Rights Reserved 16
Slide 18: Operating Profit to EBITDA
Operating Profit to EBITDA 1H Operating Profit 0.0 (0.9) (0.5) (1.4) Operating Profit to EBITDA Reconciliation 100% 1H FY24 1H FY25 Operating profit (0 .5) 0 .0 Non- operating expenses (cash) 1H FY22 1H FY23 1H FY24 1H FY25 Restructuring and other non- operating costs (0 .1) (0 .1) Impact of AASB 16
Slide 19: 1H FY25 Cashflow
1H FY25 Cashflow 1H FY24 1H FY25 Variance Cash flows from operating activities Receipts from customers (inclusive of GST) 14.0 15.1 Payments to suppliers and employees (inclusive of GST) (16.3) (15.2) Operating cash break even vs Interest received 0 .0 0 .0 Interest and other finance costs paid (0 .
Slide 20: 1H FY25 Balance Sheet
1H FY25 Balance Sheet 1H FY24 1H FY25 Variance Current assets Cash and cash equivalents 5.1 3.7 Trade and other receivables Contract assets 6.0 0 .1 6.2 0 .4 Strong Cash Position Total current assets 11.2 10 .3 (1.0 ) Non- current assets Property, plant and equipment Right- of- use assets 0 .2 0 .1
Slide 21: FY25 Outlook and Targets
FY25 Outlook and Targets Copyright © Beamtree Holdings Limited – All Rights Reserved 20
Slide 22: FY25 Outlook and Targets
FY25 Outlook and Targets Management reaffirms outlook Reported revenue growth Ongoing management of opex of delivering annual recurring expected to be ~10% for FY25. and continued reduction in cash revenue of $60m by end of burn in 2H versus 1H 2026. Forecast reported recurring revenue expected to b
Slide 23: Thank you
Thank you 22
Slide 24: Our product segments
Our product segments Copyright © Beamtree Holdings Limited – All Rights Reserved 23
Slide 25: Key Areas, Key Products and What They Do
Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Clinical rules to automate Leverages scarce clinical resources Removes duplication for experts Recurring License + volume expert decision making in through automating and in providing diagnostic